Trials / Withdrawn
WithdrawnNCT00502294
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Facet Biotech · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To compare the efficacy of visilizumab at 5 mcg/kg/day administered intravenously (IV) on Days 1 and 2 to placebo in subjects with IVSR-UC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Visilizumab (HuM291; Nuvion®) |
Timeline
- First posted
- 2007-07-17
- Last updated
- 2009-06-25
Source: ClinicalTrials.gov record NCT00502294. Inclusion in this directory is not an endorsement.